{"id":649987,"date":"2026-07-09T18:55:14","date_gmt":"2026-07-09T18:55:14","guid":{"rendered":"https:\/\/www.europesays.com\/es\/649987\/"},"modified":"2026-07-09T18:55:14","modified_gmt":"2026-07-09T18:55:14","slug":"actualidad-para-la-innovacion-farmaceutica-4","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/es\/649987\/","title":{"rendered":"Actualidad para la innovaci\u00f3n farmac\u00e9utica"},"content":{"rendered":"<p>\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"200\" src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\" class=\"isa-nb-item-img\" alt=\"\" data-lazy-src=\"https:\/\/www.europesays.com\/es\/wp-content\/uploads\/2026\/07\/astrazeneca.jpg\"\/><\/p>\n<p><strong>AstraZeneca<\/strong> ha anunciado la disponibilidad en Espa\u00f1a de tres nuevas indicaciones para <strong>durvalumab<\/strong> (Imfinzi) en <strong>c\u00e1ncer de pulm\u00f3n microc\u00edtico, vejiga y g\u00e1strico<\/strong>.\u00a0El f\u00e1rmaco <strong>redujo el riesgo de muerte un 27%<\/strong> frente al placebo, en c\u00e1ncer de pulm\u00f3n microc\u00edtico en estadio limitado (CPM-EL).<\/p>\n<p>Adem\u00e1s, este tipo de inmunoterapia demostr\u00f3 una <strong>disminuci\u00f3n del 32% del riesgo de progresi\u00f3n<\/strong>, recurrencia, cistectom\u00eda radical o muerte por cualquier causa y una <strong>reducci\u00f3n del 25 % del riesgo de muerte<\/strong>, ambos a los 24 meses, en c\u00e1ncer de vejiga m\u00fasculo-invasivo en escenario perioperatorio combinado con quimioterapia en comparaci\u00f3n con la quimioterapia neoadyuvante sola.<\/p>\n<p>Asimismo, este\u00a0anti-PD-L1 combinado a la quimioterapia est\u00e1ndar (FLOT) tambi\u00e9n <strong>disminuy\u00f3 un 29% el riesgo de riesgo de progresi\u00f3n de la enfermedad<\/strong>, <strong>recurrencia<\/strong> o <strong>muerte<\/strong> en comparaci\u00f3n a la quimioterapia sola en c\u00e1ncer g\u00e1strico y de la uni\u00f3n gastroesof\u00e1gica.<\/p>\n","protected":false},"excerpt":{"rendered":"AstraZeneca ha anunciado la disponibilidad en Espa\u00f1a de tres nuevas indicaciones para durvalumab (Imfinzi) en c\u00e1ncer de pulm\u00f3n&hellip;\n","protected":false},"author":2,"featured_media":342642,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[80],"tags":[37350,18049,82,32585,43185,95,94,25,24,76934,2217,7288,23],"class_list":["post-649987","post","type-post","status-publish","format-standard","has-post-thumbnail","category-economia","tag-abbvie","tag-astrazeneca","tag-business","tag-d1","tag-daiichi-sankyo","tag-economia","tag-economy","tag-es","tag-espana","tag-johnsonjohnson","tag-laboratorios","tag-roche","tag-spain"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@es\/116891544936992610","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/649987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/comments?post=649987"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/649987\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media\/342642"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media?parent=649987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/categories?post=649987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/tags?post=649987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}